Treatment of T-Cell (T-Lineage) Acute Lymphoblastic Leukemia

T-cell (T-lineage) acute lymphoblastic leukemia (T-ALL) is a distinct immunophenotypic subtype of ALL. T-ALL comprises approximately 25% of adult ALL cases, and its treatment follows a similar overall framework to that used for B-lineage ALL, with specific risk-stratified considerations.

Clinical Scenario

This protocol applies to patients with confirmed T-cell (T-lineage) ALL. Certain high-risk features within T-ALL — including early T-cell precursor (ETP) ALL and unfavourable oncogenetics — significantly affect treatment planning and transplant decision-making. Measurable residual disease (MRD) response is a central factor in determining escalation of care.

Treatment Approach (Overview)

For patients with T-ALL who demonstrate a poor MRD response, have ETP ALL, or carry unfavourable oncogenetic features, allogeneic transplantation is among the approaches considered in the structured protocol. For older patients with high-risk disease and an appropriate donor, a modified conditioning approach may be relevant.

The complete regimen — including full eligibility criteria, sequencing, conditioning details, and additional options — is available in the structured protocol below.